Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design

被引:83
作者
Zhao, Yanlong [1 ]
Zhang, Xi [2 ]
Chen, Yingyi [1 ]
Lu, Shaoyong [1 ]
Peng, Yuefeng [3 ]
Wang, Xiang [2 ]
Guo, Chengliang [2 ]
Zhou, Aiwu [1 ]
Zhang, Jingmiao [1 ]
Luo, Yu [1 ]
Shen, QianCheng [1 ]
Ding, Jian [2 ]
Meng, Linghua [2 ]
Zhang, Jian [1 ]
机构
[1] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ, Dept Pathophysiol,Sch Med, Shanghai 200025, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China
[3] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Biotechnol, Shenzhen 518055, Guangdong, Peoples R China
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2014年 / 5卷 / 02期
基金
中国国家自然科学基金;
关键词
PI3K; PI103; crystal structure; drug design; cancer therapy; BLOCKADE;
D O I
10.1021/ml400378e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival. Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy. We determined the crystal structure of the human PI3K alpha-PI103 complex to unravel molecular interactions. Based on the structure, substitution at the R-1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site. Interestingly, the crystal structure of the PI3K alpha-9d complex revealed that the flexibility of Lys802 can also induce additional space at the catalytic site for further modification. Thus, these crystal structures provide a molecular basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3K alpha inhibitors.
引用
收藏
页码:138 / 142
页数:5
相关论文
共 16 条
[1]   Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis [J].
Camps, M ;
Rückle, T ;
Ji, H ;
Ardissone, V ;
Rintelen, F ;
Shaw, J ;
Ferrandi, C ;
Chabert, C ;
Gillieron, C ;
Françon, B ;
Martin, T ;
Gretener, D ;
Perrin, D ;
Leroy, D ;
Vitte, PA ;
Hirsch, E ;
Wymann, MP ;
Cirillo, R ;
Schwarz, MK ;
Rommel, C .
NATURE MEDICINE, 2005, 11 (09) :936-943
[2]   PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis [J].
Castellino, R. C. ;
Muh, C. R. ;
Durden, D. L. .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (04) :380-388
[3]   PI3K: A potential therapeutic target for cancer [J].
Chen, Yingwei ;
Wang, Bao-Can ;
Xiao, Yongtao .
JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (07) :2818-2821
[4]   The Role of the PI3K-AKT Pathway in Melanoma [J].
Davies, Michael A. .
CANCER JOURNAL, 2012, 18 (02) :142-147
[5]   Phosphoinositide 3-kinase α inhibitors: a patent review [J].
Denny, William A. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (07) :789-799
[6]   A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma [J].
Fan, Qi-Wen ;
Cheng, Christine K. ;
Nicolaides, Theodore P. ;
Hackett, Christopher S. ;
Knight, Zachary A. ;
Shokat, Kevan M. ;
Weiss, William A. .
CANCER RESEARCH, 2007, 67 (17) :7960-7965
[7]   A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma [J].
Fan, Qi-Wen ;
Knight, Zachary A. ;
Goldenberg, David D. ;
Yu, Wei ;
Mostov, Keith E. ;
Stokoe, David ;
Shokat, Kevan M. ;
Weiss, William A. .
CANCER CELL, 2006, 9 (05) :341-349
[8]   Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies [J].
Foster, John G. ;
Blunt, Matthew D. ;
Carter, Edward ;
Ward, Stephen G. .
PHARMACOLOGICAL REVIEWS, 2012, 64 (04) :1027-1054
[9]   Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases [J].
Hon, W-C ;
Berndt, A. ;
Williams, R. L. .
ONCOGENE, 2012, 31 (32) :3655-3666
[10]   The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations [J].
Huang, Chuan-Hsiang ;
Mandelker, Diana ;
Schmidt-Kittler, Oleg ;
Samuels, Yardena ;
Velculescu, Victor E. ;
Kinzler, Kenneth W. ;
Vogelstein, Bert ;
Gabelli, Sandra B. ;
Amzel, L. Mario .
SCIENCE, 2007, 318 (5857) :1744-1748